KGKaitlin Garabian

Kaitlin Garabian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaitlin Garabian has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic potential of flavonols in the treatment of JCPyV

    by Evan MacLure, Kaitlin Garabian, Bethany A. O'HAra, Wenqing Yuan, Jacob Kaiserman, Avraham S. Lukacher, Sheila A. Haley, Walter J. Atwood

    JC polyomavirus (JCPyV) is a double-stranded DNA virus that causes progressive multifocal leukoencephalopathy (PML), a demyelinating disease with a high rate of morbidity and mortality. There are limited treatment options for patients diagnosed with PML, and most involve reconstitution of immunological functions. In this paper, we show that flavonols, specifically quercetin, myricetin, and fisetin, significantly reduce JCPyV infection in human glial cells. We further show that quercetin and fisetin can suppress viral spread in an already established infection, suggesting therapeutic viability of these drugs as antivirals. Additional research is required to determine the mechanism of action of flavonols in inhibiting JCPyV infection and to investigate whether these compounds have the potential to cross the blood-brain barrier in significant amounts to inhibit the virus in the brain parenchyma. IMPORTANCE: The human polyomavirus, JC polyomavirus (JCPyV), causes significant morbidity and mortality in immunosuppressed or immunomodulated patients. There are no approved antivirals to treat JCPyV-induced disease. Flavonols are naturally occurring polyphenolic compounds that are known to antagonize pathways involved in JCPyV infection. Several flavonols were found to inhibit initial JCPyV infection and viral spread in a glial cell line and in normal human glial cells. These represent a promising new treatment paradigm for patients at risk of suffering from JCPyV-induced disease.


  • Open Access

    Neurovascular pericytes are susceptible to infection by JC polyomavirus

    by Bethany A. O'HAra, Kaitlin Garabian, Wenqing Yuan, Walter J. Atwood, Sheila A. Haley

    Progressive multifocal leukoencephalopathy (PML), an often-fatal neurodegenerative disease, is caused by the neuroinvasive polyomavirus JCPyV. Peripheral organs, including the kidney, are the site of lifelong persistent infections that are asymptomatic. In a subset of immunosuppressed or immunomodulated patients, the virus invades the central nervous system infecting oligodendrocytes, which leads to the multifocal white matter disease known as PML. The mechanisms that lead to neuroinvasion by JCPyV have not been well described. The brain is protected from viruses and other pathogens by physiological barriers, including the blood-cerebrospinal fluid barrier and the blood-brain barrier. To better understand the mechanism by which the virus breaches these barriers, we focused our attention on studying virus interactions with pericytes, which are an essential component of the blood-brain barrier. We found that the virus binds to pericytes in a receptor-dependent manner and that pericytes are susceptible to JCPyV infection. Previous work from our group demonstrated that JCPyV was capable of penetrating an intact endothelial cell barrier. Once across the endothelium, JCPyV would come in direct contact with pericytes, and we hypothesize pericyte infection would amplify and facilitate robust penetration into the brain parenchyma. This is the first demonstration that pericytes, a principal component of the blood-brain barrier, are susceptible to the neuroinvasive human polyomavirus JCPyV. IMPORTANCE: JCPyV infects at least half the adult population worldwide. An asymptomatic, persistent infection is typically established in the kidney and possibly other peripheral organs. In immunosuppressed individuals, the virus can reactivate and cause progressive multifocal leukoencephalopathy, a deadly disease of the central nervous system (CNS). The pathogenic route the virus takes from the periphery to the CNS is unknown. Here, we demonstrate for the first time that JCPyV can infect human cerebrovascular pericytes, a cell type that contributes to the blood-brain barrier. This observation suggests that the virus could use the pericytes as a means to penetrate the blood-brain barrier to reach its pathogenic targets in the brain parenchyma.